Search Results - "Dougherty, Tanya"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Type 2 diabetes in the US managed care setting: the burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist by Dougherty, Tanya, Heile, Michael

    Published in The American journal of managed care (01-12-2020)
    “…Diabetes affects an estimated 34 million US adults, with type 2 diabetes (T2D) accounting for 90% to 95% of cases. The downstream consequences of uncontrolled…”
    Get full text
    Journal Article
  2. 2

    Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care by Lingvay, Ildiko, Taddei-Allen, Patty, Dougherty, Tanya

    Published in The American journal of managed care (01-12-2020)
    “…It is important to consider the safety profile of new medications in type 2 diabetes (T2D) when selecting the most appropriate treatment option for each…”
    Get full text
    Journal Article
  3. 3

    The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide by Schneider, Doron, Taddei-Allen, Patty, Dougherty, Tanya

    Published in The American journal of managed care (01-12-2020)
    “…Patient-reported outcomes (PROs), including treatment satisfaction, patient well-being, and quality of life, are becoming increasingly important contributors…”
    Get full text
    Journal Article
  4. 4

    Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care by Rodbard, Helena W, Dougherty, Tanya, Taddei-Allen, Patty

    Published in The American journal of managed care (01-12-2020)
    “…The first tablet formulation of a glucagon-like peptide-1 receptor agonist(GLP-1RA), oral semaglutide, was approved in September 2019 for the treatment of…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7